Study to Assess the Efficacy and Safety of Olanzapine and Fluoxetine Combination Versus Placebo in Patients Ages 10-17 in the Treatment of Major Depressive Episodes Associated With Bipolar I Disorder
Phase of Trial: Phase IV
Latest Information Update: 01 Mar 2015
At a glance
- Drugs Olanzapine/fluoxetine (Primary)
- Indications Bipolar I disorders
- Focus Therapeutic Use
- Sponsors Eli Lilly
- 10 Jun 2017 Biomarkers information updated
- 20 Mar 2012 Status changed from recruiting to completed as reported by ClinicalTrials.gov.
- 01 Aug 2011 Planned end date changed from 1 Nov 2011 to 1 Feb 2012 as reported by ClinicalTrials.gov.